Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 3—March 2016

Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009–2014

Benoît Henry1, Matthieu Revest, Nathalie Dournon, Loïc Epelboin, Guillaume Mellon, Guillaume Bellaud, Pierre Mordant, Damien Le Dû, Nicolas Véziris, Christine Bernard, Sébastien Morel, Stéphane Jauréguiberry, Christian Michelet, François Bricaire, Pierre Tattevin2Comments to Author , and Éric Caumes2
Author affiliations: Centre Hospitalier Universitaire Pitié Salpêtrière, Paris, France (B. Henry, N. Dournon, L. Epelboin, G. Mellon, G. Bellaud, N. Véziris, C. Bernard, S. Morel, S. Jauréguiberry, F. Bricaire, E. Caumes); Université Pierre et Marie Curie, Paris (B. Henry, L. Epelboin, N. Véziris, S. Morel, F. Bricaire, E. Caumes); Centre Hospitalier Universitaire Pontchaillou, Rennes, France (M. Revest, C. Michelet, P. Tattevin); Hôpital Européen Georges Pompidou, Paris (P. Mordant); Université Paris Descartes, Paris (P. Mordant); Centre Hospitalier de Bligny, Briis-sous-Forges, France (D. Le Dû); Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris (N. Véziris, C. Bernard); Centre d'Immunologie et des Maladies Infectieuses, Paris (N. Véziris, S. Jauréguiberry); Université Rennes 1, Rennes (C. Michelet, P. Tattevin)

Main Article

Table 1

Clinical and demographic characteristics of 20 persons with extensively drug-resistant TB, France, 2009–2014*

Characteristic Value†
Age, y (range)
37.1 (32–40.1)
Sex, no. patients
M 18
Country of origin, no. patients
Georgia 17
Armenia 2
Russian Federation
Body mass index, kg/m2 (range)
19.8 (17.7–22.7)
Past imprisonment, no. patients/no. total (%) 4/18 (22.2)
Past or present intravenous drug use, no. patients/no. total (%) 10/20 (50)
Previous history of TB, no. patients/no. total (%) 19/20 (95)
Previous anti-TB treatment, no. patients/no. total (%) 19/20 (95)
Previous thoracic surgery for TB, no. patients/no. total (%)
3/20 (15)
HIV infection, no. patients/no. total (%) 2/20 (10)
Hepatitis C virus infection, no. patients/no. total (%) 12/20 (60)
Duration of TB symptoms before current admission, y (range)
2.4 (0.5–7)
Organs involved, no. patients
Lungs 20
Weight loss, no. patients/no. total (%)‡ 15/17 (88.2)
Prolonged fever, no. patients/no. total (%)§ 8/16 (50)
Hemoptysis, no. patients/no. total (%) 13/16 (81)
Serum albumin, g/L (range) 30 (26.5–32.7)
Cavitary lesions on chest radiographs or CT scan images, no. patients/no. total (%) 19/19 (100)
Multilobar radiological involvement, no. patients/no. total (%) 18/19 (94.7)

*CT, computed tomography; TB, tuberculosis.
†Quantitative data are median (interquartile range); qualitative data are no. patients/no. with data available (%).
‡Loss of >5% of total bodyweight.
§Body temperature >38°C during at least 3 weeks.

Main Article

1Current affiliation: Université Paris Descartes, Sorbonne Paris Cité, APHP, Hôpital Necker Enfants Malades, Centre d’Infectiologie Necker Pasteur, Institut Imagine, Paris, France.

2These senior authors contributed equally to this article.

Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.